June 11, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen, CFA
312-265-9574
bsorensen@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Telomir Pharmaceuticals (TELO-NASDAQ)

TELO: Data Shows Potential Treatment for Age-Related Diseases

Telomir is developing a treatment that has the potential to lead to the extension of human life and solve many age-related health issues. We value TELO at $15.50 using discounted cash flow analysis.

Current Price (06/10/25)	$2.05
Valuation	**$15.50**

OUTLOOK

Telomir Pharmaceuticals is a preclinical stage company focused on reversing biological aging and degenerative diseases.

The company announced preclinical test results that showed Telomir-1 reversed multiple symptoms in an animal model of Wilson's disease. These results provide further proof of the potential of Telomir-1 to reduce aging-related diseases.

SUMMARY DATA

52-Week High	**$7.84**
52-Week Low	**$1.95**
One-Year Return (%)	**-62.73**
Beta	**N/A**
Average Daily Volume (sh)	**230,348**
Shares Outstanding (mil)	**30**
Market Capitalization ($mil)	**$61**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**N/A**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**

Risk Level	**High,**
Type of Stock	**Small-Growth**
Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	0 A	0 A	0 A	0 A	0 A
2024	0 A	0 A	0 A	0 E	0 E
2025	0 A	0 E	0 E	0 E	0 E
2026	0 E	0 E	0.5 E	1.0 E	1.5 E

Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	-0.45 A
2024	-0.23 A	-0.06 A	-0.20 A	-0.07 A	-0.56 A
2025	-0.07 A	-0.08 E	-0.08 E	-0.08 E	-0.31 E
2026	-0.07 E	-0.07 E	-0.08 E	-0.06 E	-0.28 E

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

UPDATE

Telomir Pharmaceuticals is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and degenerative diseases. Previously reported preclinical tests have shown evidence that Telomir-1, the company's primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, "confirms Telomir-1 can reverse biologic aging, extending life while preserving health."

The company just announced results from preclinical animal testing that further illustrate the tremendous potential that Telomir-1 has in reversing many of the worst conditions related to aging. The tests were done on an animal model of Wilson's disease, which is a rare genetic disorder that can be fatal and is caused by mutation of genes that allow the body to eliminate excess copper. Patients suffering from this condition can experience inflammation, tissue damage, and multi-organ dysfunction.

In the trial, according to the company, Telomir-1 demonstrated the statistically significant reversal of major features of the disease, including:

- Up to a 4- to 5-fold reduction in episodic tremor events.
- Normalization of swim distance, swim velocity, and exploratory behavior.
- Reversal of ataxia-like motor behaviors (e.g., abnormal body bends and turn angles).
- Approximately 50% reduction in copper accumulation in dry liver tissue.
- Marked improvement in liver and kidney histopathology, with liver and kidney scores reduced to near-normal levels.
- Normalization of ALT, AST, and bilirubin—three critical liver biomarkers. ALT and AST are enzymes elevated during liver injury, while bilirubin builds up when detoxification is impaired. Telomir-1 restored these to wild-type levels, indicating protection of liver function and copper-induced damage.

These results continue the mounting evidence that Telomir-1 has the potential to have a major impact on the worst parts of the aging process, which would have an almost unlimited market potential. We continue to recommend investors take a look at TELO ahead of the human trials that are planned for early next year.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Telomir Pharmaceuticals Income Statement and Balance Sheet							
	2023A	2024A	1Q 2525A	2Q2025E	3Q2025E	4Q2025E	2026E
Revenue	0	0	0	0	0	0	1,500,000
Operating Costs:							
General and Admistrative	(600,192)	(9,636,333)	(1,850,786)	(1,869,294)	(1,887,987)	(1,906,867)	(7,627,467)
Related party travel costs	(1,767,550)	(370,500)	0	0	0	0	0
Research and Development	(1,574,306)	(2,235,341)	(336,996)	(627,434)	(639,983)	(652,782)	(2,611,129)
Total Operating Gain/(Loss)	(3,942,048)	(12,242,174)	(2,187,782)	(2,496,728)	(2,527,969)	(2,559,649)	(8,738,596)
Interest Income/(expenses)	(1,643,049)	(4,290,542)	7,954	15,445	15,599	15,755	63,022
Loss on extingushment of debt	(7,486,767)	0	0	0	0	0	0
Other Income/(Expenses)	-	-	-	-	-	-	-
Net Gain/(Loss)	(13,071,864)	(16,532,716)	(2,179,828)	(2,481,283)	(2,512,370)	(2,543,894)	(8,675,574)
Diluted loss per share	(0.45)	(0.56)	(0.07)	(0.08)	(0.08)	(0.08)	(0.28)
Diluted Wtd Common Shares Outstanding	29,017,857	29,539,219	29,762,671	29,609,814	29,905,912	30,204,971	30,507,021
Assets							
Current Assets							
Cash and cash equivalents	1,231	1,266,131	402,999	3,334,638	2,834,442	2,409,276	2,047,885
Other Assets	433,994	57,874	88,189	207,347	209,420	211,515	213,630
Total Current Assets	435,225	1,324,005	491,188	3,541,985	3,043,863	2,620,791	2,261,514
Long Term Assets	4,338,543	-	-	-	-	-	-
Total Assets	4,773,768	1,324,005	491,188	3,541,985	3,043,863	2,620,791	2,261,514
Current Liabilities							
Trade accounts payable	707,187	587,536	558,862	506,479	349,471	241,135	166,383
Other Current Liabilities	628,377	93,432	93,432	93,432	94,366	95,310	96,263
Total Current Liabilities	1,335,564	680,968	652,294	599,911	443,837	336,445	262,646
Long-term Liabilities	-	-	-	-	-	-	-
Total Liabilities	1,335,564	680,968	652,294	599,911	443,837	336,445	262,646
Common Stock	-	-	-	-	-	-	-
Additional Paid-in Capital	17,502,346	31,239,895	32,615,580	28,140,559	28,421,965	28,706,184	28,993,246
Accumulated Deficit	(14,064,142)	(30,596,858)	(32,776,686)	(25,198,485)	(25,821,939)	(26,421,838)	(26,994,378)
Total SH deficit/(equity)	3,438,204	643,037	(161,106)	2,942,074	2,600,026	2,284,346	1,998,868
Total Liabilities and SH deficit/(equity)	4,773,768	1,324,005	491,188	3,541,985	3,043,863	2,620,791	2,261,514

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.